Methotrexate for psoriasis in the era of biological therapy

Richard Warren, R. B. Warren, R. J G Chalmers, C. E M Griffiths, A. Menter

    Research output: Contribution to journalArticlepeer-review


    Methotrexate's traditional role as a first line agent for moderate to severe psoriasis is being challenged by the rapid and growing use of biological therapies. A recent study comparing adalimumab with methotrexate showed significantly superior efficacy of adalimumab over methotrexate over 16 weeks. Although it is inexpensive, the future use of methotrexate may be compromised by its unpredictable response and toxicity, and by the introduction of newer, more effective biological therapies. However, recent advances in the screening of liver fibrosis by monitoring serum levels of the aminoterminal peptide fragment of type III procollagen have reduced the need for liver biopsy. Furthermore, the potential for personalized methotrexate use by application of modern pharmacogenetics and pharmacokinetics may ensure its place as a first-line agent for the treatment of psoriasis for the foreseeable future. © 2008 The Author(s).
    Original languageEnglish
    Pages (from-to)551-554
    Number of pages3
    JournalClinical and Experimental Dermatology
    Issue number5
    Publication statusPublished - Sept 2008


    Dive into the research topics of 'Methotrexate for psoriasis in the era of biological therapy'. Together they form a unique fingerprint.

    Cite this